Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) | MicrobiomeTrials← Back to trialsNCT07513324
Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-07-01Est. Completion: 2028-01-01
Enrollment target: 116 participants Locations- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Merkel Cell CarcinomaCutaneous Squamous Cell CarcinomaBasal Cell CarcinomaTriple Negative Breast CancerNon-Small Cell Lung CancerOropharynx Squamous Cell Carcinoma
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced…
Birmingham, United StatesCompleted Oct 31, 2024
Squamous Cell Carcinoma of Oropharynx
Prospective pilot study, non-interventional, of a biological/radiological nature, which involves the collection of tissu…
Rome, ItalyEst. completion Jul 24, 2026